LEO Pharma Announces Publication of Chronic Hand Eczema Phase 3 Data in The Lancet19.7.2024 08:00:00 CEST | LEO Pharma
The Lancet publishes data from the pivotal DELTA 1 and DELTA 2 trials, marking the first time an investigational topical pan-Janus kinase (JAK) inhibitor for chronic hand eczema (CHE) has been featured in the journal.1 The DELTA 1 and DELTA 2 trials investigated the safety and efficacy of investigational delgocitinib cream in adult patients with moderate to severe CHE.2,3